Under construction – not a live service
Sign in
Not yet taking people in ItalyPhase 2

Testing minocycline added to usual medicine for adults with depression

Tests minocycline added to usual medicine in adults with depression.

Key facts

Who runs it
Provincia Lombardo Veneta Dell’Ordine Ospedaliero Di San Giovanni Di Dio Fatebenefratelli
Where
Brescia, ItalySee the 2 sites
Registry title
Targeting inflammation in depression using Minocycline: a patient stratification approach using peripheral inflammatory biomarkers and MRI
Status
Not yet recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
10 Aug 2022
Expected to end
31 Dec 2027
Type of study
Interventional
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with major depression who still have symptoms despite their current SSRI antidepressant and who have raised blood inflammation (CRP).

Age
18 to 65 years
Sex
Women and men can join.
Disease stage
Major depressive disorder without psychosis (DSM-V diagnosis confirmed by SCID); CRP level above 2 mg/L.
Earlier treatment
Must be on a stable antidepressant for at least 8 weeks, with no response to the current SSRI after at least 8 weeks and to one other SSRI in the past. Must tolerate the current SSRI. Cannot have had tetracycline treatment in the previous 2 months.
Biomarker or test result
CRP level above 2 mg/L (and not above 20 mg/L).

Main reasons for not taking part

  • Active suicidal thoughts
  • Main diagnosis of bipolar disorder, obsessive-compulsive disorder, eating disorder or PTSD
  • History of substance or alcohol abuse
  • Acute infection, autoimmune or inflammatory disease, or CRP above 20 mg/L
  • Severe kidney failure, liver problems, or allergy to Minocycline or other tetracyclines

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Being male or female depressed patients (aged 18-65); 2. Having a current DSM-V diagnosis of nonpsychotic major depressive disorder confirmed by SCID; 3. Being non-responder to a current SSRI for at least 8 weeks, and historically to one other SSRI; 4. Being in stable antidepressant therapy for at least 8 weeks; 5. Being tolerant to the current SSRI; 6. Accepting Minocycline treatment; 7. Having CPR level> 2 mg/L; 8. Having signed and dated an informed consent to participate in the study; 9. Having no contraindications to receive treatment with Minocycline

Who cannot take part

  • Having active suicidal ideation; 2. Having a primary diagnosis of bipolar disorder, obsessive-compulsive disorder, eating disorder, PTSD; 3. Having a history of substance/alcohol abuse; 4. Having received tetracycline therapy within the previous 2 months; 5. Having a history of sensitivity to this class of drugs; 6. Having acute infections or an autoimmune or inflammatory disorder; 7. Having CRP>20 mg/L, as indicates acute infection or other major pathology; 8. Being sensitive to Minocycline; 9. Having a history of severe allergy or hypersensitivity to drugs; 10. Being hypersensitive to the active substance, to other tetracyclines or to any of the excipients; 11. Having severe renal failure; 12. Having hepatic dysfunction; 13. Being pregnant and in lactation; 14. (for MRI) Having pacemakers, electromechanical devices, ferromagnetic vascular clips, cochlear implants, stapedial prostheses, ferromagnetic foreign bodies, sickle cell anemia

Where in Italy

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaBrescia, ItalyNot yet recruiting
  • Provincia Lombardo Veneta Dell’Ordine Ospedaliero Di San Giovanni Di Dio FatebenefratelliBrescia, ItalyNot yet recruiting

About the trial

What the trial wants to find out

To evaluate an improvement in the peripheral inflammatory status in depressed patients after 8 weeks of treatment with Minocycline in addition to their current pharmacological treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
Targeting inflammation in depression using Minocycline: a patient stratification approach using peripheral inflammatory biomarkers and MRI
Plain-language title
Testing minocycline added to usual medicine for adults with depressionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 10 November 2026.
Record updated
9 November 2026